Related Experiment Video
Updated: Jul 19, 2026
04:04
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
[Intraoperative therapeutic intensification techniques in locally advanced abdominal sarcomas]
José Luis García Sabrido1, Enrique Velasco Sánchez, Felipe Calvo
1Servicio de Cirugía General y del Aparato Digestivo, Universidad Complutense, Hospital General Universitario Gregorio Marañón. Madrid, España.
Cirugia Espanola
|October 17, 2006
Summary
Intraoperative radiotherapy (IORT) improves outcomes for advanced abdominal sarcomas. Hyperthermic intraoperative intraperitoneal chemotherapy (HIIC) offers a feasible treatment option for peritoneal sarcomatosis.
Area of Science:
- Oncology
- Surgical Oncology
Background:
- Sarcomas are rare mesenchymal tumors with challenging management due to variable characteristics.
- Locally advanced abdominal sarcomas and peritoneal sarcomatosis present significant therapeutic difficulties.
Purpose of the Study:
- To evaluate the efficacy of intraoperative radiotherapy (IORT) and hyperthermic intraoperative intraperitoneal chemotherapy (HIIC) in treating advanced abdominal sarcomas and peritoneal sarcomatosis.
- To assess the impact of these intensified intraoperative techniques on patient survival and local control.
Main Methods:
- Retrospective analysis of 20 patients with advanced abdominal sarcoma and 5 with peritoneal sarcomatosis treated between 1996 and 2005.
- Advanced abdominal sarcomas underwent complete/maximal resection followed by IORT.
- Peritoneal sarcomatosis was treated with massive cytoreduction followed by HIIC.
Main Results:
- Advanced abdominal sarcomas without sarcomatosis showed a 65% survival rate at 26 months.
- In peritoneal sarcomatosis, 3 out of 5 patients were alive at 20 months follow-up, with 2 disease-free.
Conclusions:
- IORT combined with radical surgery appears to enhance local control and survival in advanced abdominal sarcomas.
- Maximal cytoreduction plus HIIC is a feasible therapeutic strategy for peritoneal sarcomatosis with curative potential.